Kathryn Edmiston

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype

Ottó Walter, Manju L. Prasad, Shaolei Lu et al. · Human Pathology · 2009 · 112 citations

Breast Oncology, Medicine, Pathology +9

Teaching of Independent Exercises for Prehabilitation in Breast Cancer

Jennifer Baima, Sara-Grace Reynolds, Kathryn Edmiston et al. · Journal of Cancer Education · 2015 · 49 citations

Nursing, Physical Activity, Prehabilitation +10

HER-2 Status in Breast Cancer

Armando Ciampa, Bo Xu, Gamze Ayata et al. · Applied immunohistochemistry & molecular morphology · 2006 · 42 citations

Tumor Biology, Gene Amplification, Metastatic Breast Cancer +11

Attitudes toward Risk Factor Behavior of Relatives of Cancer Patients

Jean L. Kristeller, James R. Hébert, Kathryn Edmiston et al. · Preventive Medicine · 1996 · 39 citations

Family Medicine, Risk Communication, Cancer Risk +5